For multi-site operators, mental health and outpatient groups, private equity-backed platforms, and larger organizations weighing an exit — what the business is worth, who competes to buy it, and how structure decides what you actually receive.
This page is for a different seller than our treatment center owners. If you run a single detox or residential program, start there. This page is for the owner of something larger: multiple locations, a mental health group with several clinics, a platform backed by investors, a larger outpatient network, or an organization weighing a sale to private equity or a health system.
We advise operators and platforms nationwide, in all fifty states. The mechanics of the transaction are the same. The buyer pool, the valuation logic, the structure, and the diligence are not — and the differences are where the money is.
The distinction is not size for its own sake. A platform is a business a buyer can scale without the seller: centralized leadership, repeatable clinical and intake processes, systems that produce usable data, and a footprint that can absorb acquisitions. A single strong facility is valued on its own earnings. A platform is valued on its earnings and on the buyer's ability to add to it.
This is why two businesses with identical EBITDA can sell for different multiples. The buyer of a platform is also buying the next three acquisitions. That is worth paying for, and it is worth preparing for — usually twelve to twenty-four months before you go to market.
Platforms trade at higher multiples, for three reasons: scale reduces the risk in any one location, a larger buyer pool competes for them, and institutional buyers can finance them. Below a certain earnings threshold, the buyer is usually an individual or a small operator paying a small-business multiple. Above it, the buyer is a fund or a strategic acquirer comparing you to other platforms.
The threshold is not a single number, and we will not invent one for you. What matters is that if you are anywhere near it, the incremental value of growing earnings is not linear — crossing into a different buyer pool can change the multiple as well as the number it is applied to. That is a planning question worth having early, because it changes whether you should sell now or add a location first.
Rollover equity means you sell most of the business and keep a minority stake in the buyer's larger platform, paid out when that platform is sold again. It is common in platform deals and can be the difference between a good outcome and an exceptional one — or between a real exit and a stake you cannot sell.
It is not a discount, and it is not free money. Three questions decide whether it is good for you:
An earn-out pays you more if agreed metrics are hit after closing — usually census, revenue, or EBITDA over one to three years. The metric is the whole negotiation. An earn-out tied to census in a facility you no longer operate is not compensation; it is a wager on someone else's management.
Where earn-outs work: they bridge a genuine disagreement about future performance, they are tied to measures you can materially influence during a defined transition period, and the accounting is unambiguous. Where they fail: when the seller cannot affect the metric, when definitions are loose, or when the buyer has discretion over what counts.
Institutional buyers commission a quality of earnings review — a third-party rebuild of your reported earnings from source documents, not from your P&L. It tests revenue recognition, payer concentration, related-party arrangements, deferred maintenance and capital needs, and the sustainability of the add-backs management proposed.
By the time it happens, the headline price is already agreed. This is why the review feels like a repricing: it is the first time a stranger has rebuilt the number from bank statements. We prepare clients for it before market, which is the single most effective thing a seller can do to protect their price.
Mental health and substance use businesses attract overlapping but distinct buyer pools. Mental health groups — therapy practices, psychiatry, PHP and IOP, telehealth platforms — are bought for payer mix, clinician retention, and referral stability, with relatively lighter regulatory scrutiny. Substance use treatment carries heavier diligence around 42 CFR Part 2, EKRA, medical necessity documentation, and licensed bed capacity.
If you own both, the two can be worth more sold together as a continuum, or separately to different pools. It is worth modelling rather than assuming.
These transactions have constraints that for-profit deals do not: charitable asset rules, attorney general review in some states, board and community obligations, and in some cases a requirement to preserve the mission or the service population. The buyer pool is narrower and the timeline longer.
They also have real advantages: mission alignment can matter more than price to the right acquirer, and the assets are often irreplaceable in their market. We handle these on their own terms rather than forcing them through a for-profit template.
You keep running the business. We run the sale.
Begin with a confidential valuation and a preparation period aimed at the buyer you actually want. Institutional buyers commission their own quality of earnings review, so the work is in getting your adjusted EBITDA and per-location reporting ready to survive that rebuild before the business goes to market.
Private equity buys on a thesis and a deadline, pays for fit and scale, and typically wants you to stay through a transition and often to roll equity. A strategic operator buys capability and census, moves faster, and is usually more flexible on structure. Which is better depends on how much cash you need now and whether you want a second bite at a future sale.
Only if you are comfortable being a minority holder in a business you do not control, waiting for someone else to sell it again. It can meaningfully increase total proceeds. It is the wrong structure if you need to be fully liquid, or if the governance and liquidity rights are thin.
Expect nine to eighteen months. Institutional diligence, a quality of earnings review, per-state licensure approvals, and change-of-ownership filings all take time, and the sequence between closing on the business and closing on the licenses has to be planned deliberately.
Not always, but reviewed or audited statements reduce the discount a buyer applies to uncertainty, and they make a quality of earnings review faster and less contentious. If your statements are compiled or cash-basis only, that is a preparation item, not a disqualifier.
Yes. Carve-outs, single-state divestitures, and separate sale of a level of care are all common, and they can produce more total value than selling everything together. They require clean standalone financials to work.
Bring us in before you sign a letter of intent. A fund that has already chosen you is leverage, and the structure — cash at close, rollover, earn-out definitions, governance — is where the difference between two superficially similar offers is decided.
Single detox, residential, or treatment center? Start here.
Learn more →Model an indicative enterprise value from adjusted EBITDA.
Learn more →Multi-state portfolios, sale-leasebacks, and clean single-site deals.
Learn more →Deal structure, diligence, and licensing, in plain language.
Learn more →No obligation, no fee, and nothing shared without your written consent. Tell us about the facility and we will tell you what it is likely worth and what a buyer would need to see.
Phone
(516) 262-3848
